PMID- 16565322
OWN - NLM
STAT- MEDLINE
DCOM- 20060810
LR  - 20071115
IS  - 0741-5400 (Print)
IS  - 0741-5400 (Linking)
VI  - 79
IP  - 6
DP  - 2006 Jun
TI  - RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness 
      to chemoattractants and impairs desensitization.
PG  - 1357-68
AB  - Chemokines bind receptors that are members of the G-protein-coupled receptor 
      family. Chemokine receptors transduce intracellular signals by activating 
      heterotrimeric G-proteins. Acting to limit and modulate heterotrimeric G-protein 
      signaling is a family of proteins, termed regulator of G-protein signaling (RGS). 
      Two of these proteins, RGS1 and RGS13, are well-expressed in germinal center B 
      cells and many Burkitt's lymphoma cell lines. Reducing RGS13 and to a lesser 
      extent RGS1 expression in a Burkitt's lymphoma cell line enhances responsiveness 
      to two chemokines, CXC chemokine ligand 12 (CXCL12) and CXCL13, and reducing both 
      mRNAs augments the responses more dramatically. The double knock-down (KD) cells 
      respond better to restimulation with CXCL12 or CXCL13 after a primary stimulation 
      with CXCL12 than do the control cells. The double-KD cells also exhibit a greater 
      propensity to polarize and to develop multiple small lamellipodia. These results 
      indicate that RGS1 and RGS13 act together to regulate chemokine receptor 
      signaling in human germinal center B lymphocytes and provide evidence that they 
      contribute significantly to the rapid desensitization of the signaling pathway.
FAU - Han, Jang-Il
AU  - Han JI
AD  - National Institute of Allergy and Infectious Diseases, National Institutes of 
      Health, 10 Center Dr., Bethesda, MD 20892, USA.
FAU - Huang, Ning-Na
AU  - Huang NN
FAU - Kim, Dong-Uk
AU  - Kim DU
FAU - Kehrl, John H
AU  - Kehrl JH
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060324
PL  - England
TA  - J Leukoc Biol
JT  - Journal of leukocyte biology
JID - 8405628
RN  - 0 (CXCL12 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (RGS Proteins)
RN  - 0 (RGS1 protein, human)
RN  - 0 (RGS13 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - B-Lymphocytes/*drug effects/physiology
MH  - Burkitt Lymphoma/pathology
MH  - Cell Line, Tumor/drug effects
MH  - Chemokine CXCL12
MH  - Chemokines, CXC/pharmacology
MH  - Chemotaxis/*drug effects
MH  - Genetic Vectors/genetics
MH  - Germinal Center/*cytology
MH  - Humans
MH  - Lentivirus/genetics
MH  - Platelet Activating Factor/pharmacology
MH  - RGS Proteins/genetics/*physiology
MH  - *RNA Interference
MH  - RNA, Messenger/*antagonists & inhibitors/genetics
MH  - Recombinant Fusion Proteins/pharmacology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/drug effects/physiology
EDAT- 2006/03/28 09:00
MHDA- 2006/08/11 09:00
CRDT- 2006/03/28 09:00
PHST- 2006/03/28 09:00 [pubmed]
PHST- 2006/08/11 09:00 [medline]
PHST- 2006/03/28 09:00 [entrez]
AID - jlb.1105693 [pii]
AID - 10.1189/jlb.1105693 [doi]
PST - ppublish
SO  - J Leukoc Biol. 2006 Jun;79(6):1357-68. doi: 10.1189/jlb.1105693. Epub 2006 Mar 
      24.